Heme is a cofactor of central importance across biology and plays vital roles in diverse processes including energy production, oxygen transport, gas sensing, signaling ([@r1]), and catalysis ([@r2]). Its inherently high and tunable redox potential together with its diverse ligand-binding properties make it an extremely versatile cofactor suited to a broad range of chemistries. Free heme redox cycles in the aerobic and reducing cellular environment, which can induce potentially cytotoxic oxidative stress. To minimize this, both heme levels and reactivity are restricted in several ways, including sequestering it into protein scaffolds that determine the selectivity and specificity of its chemistry, degradation, export, and inactivation by physical processes such as crystallization ([@r2][@r3]--[@r4]). Cells maintain labile pools of critical cofactors to meet rapidly changing metabolic demands. Such pools for transition metal cofactors including iron and zinc, which can also be cytotoxic, have been quantitatively defined using an extensive toolkit ([@r5], [@r6]). However, similar and generally accessible tools for studying labile heme pools in live cells have not been widely available, and this has precluded achieving a detailed and quantitative understanding of cellular heme pool composition and dynamics under both physiologic and perturbed states.

We have been particularly interested in characterizing labile heme pools in the human malarial parasite, *Plasmodium falciparum*. This pathogen is a major cause of the 214 million cases and 438,000 deaths per year due to malaria ([@r7]). Several aspects of heme metabolism in *P. falciparum* are counterintuitive, and its exquisite sensitivity to heme-interacting antimalarial drugs suggests a critical and finely balanced role for heme in its biology. During development within red blood cells (RBCs), *P. falciparum* takes up and digests between 30 and 70% of the hemoglobin in a specialized subcellular digestive vacuole (DV) to release peptides and heme ([@r8][@r9][@r10]--[@r11]). The majority of this heme is converted into crystalline hemozoin, which is relatively redox-inert ([@r8], [@r11]). Although the extent of hemoglobin digestion and heme crystallization is relatively lower in early-stage parasites (rings), this progressively increases as parasites develop through mid (trophozoite) and late (schizont) stages.

It is presently unknown whether hemoglobin-derived heme is quantitatively converted into hemozoin and exclusively confined to the DV, or whether it escapes the DV to accumulate in other compartments such as the parasite cytoplasm during normal development. Such a heme pool may be important for meeting metabolic needs, signaling to coordinate DV biochemistry with cytosolic and nuclear processes, or simply a consequence of obligate hemoglobin degradation by the parasite. Along these lines, despite liberating large quantities of heme from hemoglobin that should be more than adequate to meet the parasite's needs, the *P. falciparum* genome encodes a complete heme biosynthetic pathway that appears to be active in blood-stage parasites ([@r12][@r13]--[@r14]). Nevertheless, de novo heme biosynthesis is dispensable during the blood-stage infection, as the genes encoding δ-aminolevulinic acid synthase (ALAS) and ferrochelatase that are required for de novo heme biosynthesis can be deleted without observable defects in parasite growth ([@r13], [@r15]). Based on these studies, it has been suggested that hemoglobin-derived heme may escape the DV to completely meet the parasite's heme requirement. However, the physiologic levels of bioavailable heme, irrespective of its source, are yet to be defined.

Further highlighting the importance of heme biochemistry in the parasite is the potent antimalarial activity of chloroquine, an exemplar of the heme-binding 4-aminoquinoline drug class. These compounds accumulate within the parasite's DV to disrupt hemozoin formation, and the noncrystallized heme is proposed to escape the DV to cause toxicity ([@r11]). Consistent with this, electron spectroscopic imaging of fixed, chloroquine-treated parasites revealed a qualitative increase in cytosolic iron content, suggestive of increased heme content in the parasite's cytoplasm ([@r16]). However, heme can be degraded in a glutathione-dependent manner to release iron ([@r17]), the extent of which cannot be inferred from the data. Fractionation studies on chloroquine-treated parasites also support an increase in labile heme, but its precise subcellular distribution cannot be inferred ([@r16]). Thus, direct and quantitative evidence of cytosolic heme accumulation in chloroquine-treated parasites is still lacking, despite the central importance of this knowledge to understanding the mechanism of action of arguably the most successful antimalarial drug class used to date.

Here, we have addressed the fundamental challenge of directly quantifying labile heme in live cells by systematically developing, validating, and optimizing a genetically encoded fluorescence-based heme biosensor. Using the optimized biosensor, we demonstrate that *P. falciparum* maintains a labile cytosolic heme pool throughout its blood-stage development. Furthermore, we directly show that disrupting heme sequestration in the DV using a heme-binding antimalarial drug causes a significant increase in the concentration of cytosolic labile heme, thus directly linking chloroquine to cell-wide heme perturbation. We believe that this biosensor will be broadly useful for directly interrogating heme biology in *P. falciparum* and in other organisms.

Results {#s1}
=======

Design and Characterization of a Quenched Fluorescence Heme Biosensor. {#s2}
----------------------------------------------------------------------

We initially set out to design a FRET-based heme sensor constructed analogously to some previously described small-molecule biosensors, in which an analyte-sensing domain is flanked by a donor--acceptor pair ([@r18]). Our data indicated, however, that although heme sensors of this design exhibit FRET in the *apo*-state, heme binding quenched energy transfer from the donor. In our proof-of-concept sensor, we selected enhanced cyan and yellow fluorescent proteins (ECFP and EYFP), respectively, as the donor and acceptor, and *P. falciparum* histidine rich protein 2 (*Pf*HRP2) without its signal peptide as the heme-binding domain ([Fig. 1*A*](#fig01){ref-type="fig"}). We chose *Pf*HRP2 as the heme sensor domain as this protein was previously shown to noncooperatively bind ∼15--18 heme molecules/monomer with modest (∼0.3 µM) apparent affinity ([@r19], [@r20]). This modest affinity for heme minimizes the potential for a sensor based on this protein to act as a heme sink in cells, especially if a minimal length *Pf*HRP2 fragment with reduced heme-binding stoichiometry can be defined (see below). *Pf*HRP2 is nonessential to the parasite and is predominantly trafficked to the infected RBC cytosol or the parasite's DV to a lesser extent ([@r20], [@r21]). Thus, *Pf*HRP2 does not play an essential role in the parasite's cytosol, apicoplast, or mitochondrial compartments, and expressing it (or fusions thereof) in these compartments should not interfere with its physiologic role(s).

![Design and characterization of the initial heme biosensor. (*A*) Schematic of CHY heme sensor and CSY nonsensing control. (*B*) Representative difference absorption spectrum of the CHY during titration with heme. (*C*) Heme-binding isotherms based on ∆*A*~416nm~ Soret peak absorbance for CHY (blue circles), CSY (red triangles), ECFP (cyan inverted triangles), and EYFP (yellow diamonds). The solid line indicates the best fit for the CHY data using a single-site binding model and accounting for ligand depletion. (*D*) Normalized fluorescence intensity spectra for CHY titrated with heme. (*E*) Normalized *E*~DA~ for CHY (blue circles) and CSY (red triangles) fitted to a single-exponential decay model (blue solid line) and a line (red dashed line), respectively. (*F*) Dependence of ECFP fluorescence lifetime on heme concentration for the CHY (blue circles), CH (green squares), ECFP (cyan inverted triangles), and CSY (red triangles) constructs.](pnas.1615195114fig01){#fig01}

Therefore, we created a test construct (CHY) in which *Pf*HRP2 was flanked by ECFP and EYFP. We also made a control construct (CSY)---which should exhibit heme-independent and constitutive FRET ([@r22])---by substituting the *Pf*HRP2 sensor domain for a (Gly~4~Ser)~3~ peptide spacer.

We recombinantly expressed and purified CHY and CSY to characterize their biochemical and spectroscopic properties in vitro ([Fig. S1](#sfig01){ref-type="fig"}). We first tested whether flanking *Pf*HRP2 by ECFP and EYFP interfered with its heme-binding properties. Heme binding to *Pf*HRP2 occurs via bis-histidyl ligation, which causes a shift in the heme Soret peak absorbance from ∼396 to 416 nm. Monitoring this change by UV-visible spectroscopy while titrating heme levels facilitates determination of heme-binding stoichiometry and apparent heme-binding affinity to *Pf*HRP2 ([@r19], [@r23]). Heme titrations with CHY produced the expected increase in absorbance at 416 nm, consistent with binding to *Pf*HRP2 ([Fig. 1*B*](#fig01){ref-type="fig"}). Analysis of these data by breakpoint detection and fitting to a ligand binding with depletion model ([@r23]) ([Fig. 1*C*](#fig01){ref-type="fig"}), respectively, revealed that CHY bound ∼15 heme equivalents per monomer with an apparent *K*~D~ value of ∼0.25 µM. These data are in good agreement with previously published data obtained for recombinant *Pf*HRP2 ([@r19], [@r20]), indicating that fusion to ECFP and EYFP did not significantly alter its heme-binding properties. Furthermore, no heme binding to ECFP, EYFP, and CSY could be detected in similar heme titration experiments ([Fig. 1*C*](#fig01){ref-type="fig"}), indicating that *Pf*HRP2 accounts for all spectroscopically detectable heme binding to CHY.

![SDS/PAGE purity analysis of recombinant CHY, CSY, ECFP, EYFP, and CH used for fluorescence lifetime spectroscopy.](pnas.1615195114sfig01){#sfig01}

Next, we assessed the FRET properties of CHY and CSY. Based on earlier studies with model FRET constructs of the design CFP--linker--YFP ([@r22]), we expected that CHY and CSY would produce efficient FRET in the absence of heme. Indeed, for both CHY and CSY, direct ECFP excitation at 420 nm produced emission spectra with maxima at 475 nm (ECFP emission) and 525 nm (EYFP emission) ([Fig. 1*D*](#fig01){ref-type="fig"}). The latter emission peak is indicative of FRET between the ECFP donor and EYFP acceptor. Further supporting this interpretation, when a 1:1 mixture of ECFP and EYFP was excited at 420 nm, only the characteristic ECFP emission spectrum with a maximum at 475 nm but no emission maximum at 525 nm was detected. This indicates that interaction of the donor and acceptor pair in *trans* is insufficient to produce the observed FRET. We then titrated CHY and CSY with heme while exciting at 420 nm. For CHY, detected YFP emission sharply decreased upon adding heme, and at 10 µM heme, no EYFP emission was detectable ([Fig. 1 *D* and *E*](#fig01){ref-type="fig"}). For CSY, only a modest decrease in EYFP emission was detected upon titrating heme ([Fig. 1 *D* and *E*](#fig01){ref-type="fig"}). These data are consistent with CHY functioning as a "turn-off" sensor upon heme binding to the *Pf*HRP2 domain.

To gain insight into why CHY functioned as a turn-off heme sensor, we compared heme-dependent ECFP fluorescence lifetimes ([Fig. S2](#sfig02){ref-type="fig"}) for ECFP, CSY, CHY, and an ECFP--*Pf*HRP2 fusion (CH) ([Fig. 1*F*](#fig01){ref-type="fig"}). ECFP fluorescence lifetime in both CHY and CH decreased upon titrating heme but was unchanged for ECFP and CSY. With no heme bound, *Pf*HRP2 exists as a random coil, but upon binding heme undergoes a conformational change to adopt partial 3~10~-helical structure ([@r19]). A transition from random coil to a more rigid helical structure that physically separates the donor--acceptor pair could reduce energy transfer from ECFP to EYFP. However, this would be accompanied by an increase in ECFP lifetime during heme titrations, rather than the observed decrease. This indicated that our sensor did not behave like a classical FRET sensor. Heme-dependent changes in ECFP fluorescence lifetime in the CH and CHY constructs could be due to dynamic or static quenching of the emitted ECFP or EYFP fluorescence by heme bound to *Pf*HRP2. This mechanism is consistent with the decrease in ECFP lifetime observed in our experiments upon heme binding, and is supported by an earlier observation showing that irreversible heme binding to a cytochrome *b*~562~--GFP fusion strongly quenched GFP fluorescence ([@r24]).

![Diagram of the fluorescence lifetime instrumentation setup.](pnas.1615195114sfig02){#sfig02}

Optimization of Initial Heme Biosensor Design. {#s3}
----------------------------------------------

Having established that inserting *Pf*HRP2 between ECFP and EYFP produces a heme sensor, we sought to improve this design by defining a minimal *Pf*HRP2 fragment that preserved heme binding while maximizing heme-dependent changes in energy transfer. Based on model studies, these parameters may be simultaneously optimized by selecting shorter linkers between donor and acceptor fluorophores ([@r22]). We also reasoned that reducing the heme-binding capacity of our sensor together with its inherently modest binding affinity would minimize the potential for the sensor to act as a heme sink.

We made a minilibrary of *Pf*HRP2 fragments containing variable numbers of heme-binding motifs ([@r25], [@r26]) and cloned these between ECFP and EYFP to create several sensors. These are annotated as CH~*x*~Y, where *x* is the number of *Pf*HRP2-derived amino acids comprising the heme binding domain ([Fig. 2*A*](#fig02){ref-type="fig"} and [Fig. S3](#sfig03){ref-type="fig"}). We recombinantly expressed and purified these constructs, and determined that all bound heme with apparent affinities similar to full-length CHY and stoichiometries that were directly proportional to the length of the heme-binding domain ([Fig. 2*B*](#fig02){ref-type="fig"} and [Fig. S4](#sfig04){ref-type="fig"}). In addition, the heme-sensing dynamic range was improved with shorter heme-binding domains ([Fig. 2*C*](#fig02){ref-type="fig"}). Because the *apo*-sensor exhibited FRET, but energy transfer from ECFP to EYFP decreased due to a quenching mechanism rather than a change in the spatial relationship between the donor and acceptor pair induced by heme binding (i.e., classical FRET), we defined an operational metric, *E*~DA~, to reflect the effective efficiency of donor-to-acceptor energy transfer. We calculated this identically to *E*~FRET~ ([@r27]) but use the *E*~DA~ nomenclature to specify that the original FRET signal from the *apo*-sensor changes in response to heme binding through quenching of donor energy transfer. Using this metric, we determined that *E*~DA~ for all sensors decreased upon heme binding, with half-maximal values between 2 and 6 µM heme ([Figs. S5](#sfig05){ref-type="fig"} and [S6](#sfig06){ref-type="fig"}). Sensors with shorter *Pf*HRP2 sensing domain fragments exhibited greater *E*~DA~ dynamic range ([Fig. 2*C*](#fig02){ref-type="fig"} and [Fig. S5](#sfig05){ref-type="fig"}).

![Optimization to improve heme biosensor dynamic range. (*A*) Schematic of the minilibrary of *Pf*HRP2 fragments (shown in blue) evaluated for improved energy transfer properties. The fragment length (in amino acids) and the amino acid coordinates for mapping each fragment onto full-length *Pf*HRP2 are indicated. Apparent dissociation constants (*K*~D,app~) are also shown. (*B*) Heme-binding stoichiometry varies linearly with length of the *Pf*HRP2-derived heme-binding domain. (*C*) Dependence of ∆*E*~DA~ \[=*E*~DA~ (no heme) -- *E*~DA~ (saturating heme)\] on length of the PfHRP2-derived heme-binding domain. (*D*) *E*~DA~ dependence on heme concentration for optimized CH~49~Y (blue hollow circles) relative to the original sensor CHY (filled blue circles) and CSY (red triangles). (*E*) Calibration curve relating normalized *E*~DA~^CH49Y^ to heme concentration ([*Materials and Methods*](#s7){ref-type="sec"}).](pnas.1615195114fig02){#fig02}

![SDS/PAGE purity analysis of recombinant minilibrary of truncated biosensors.](pnas.1615195114sfig03){#sfig03}

![Heme-binding titrations of truncated sensor minilibrary showing heme-binding stoichiometry and apparent heme-binding affinity.](pnas.1615195114sfig04){#sfig04}

![Heme-dependent changes in donor--acceptor energy transfer efficiency for the minilibrary of truncated sensors.](pnas.1615195114sfig05){#sfig05}

![Effect of truncating the heme-binding domain on sensitivity (IC~50~) of the resulting biosensor. Generally, shorter heme-binding domains result in sensors with lower sensitivity (higher IC~50~). CH~49~Y was the most sensitive of the truncated biosensor family with the second-largest dynamic range (after CH~18~Y) and was therefore chosen as the optimal biosensor design.](pnas.1615195114sfig06){#sfig06}

We selected the CH~49~Y sensor construct for further development due to its improved dynamic range over CHY and retained responsiveness to heme. To preserve the option of using EYFP fluorescence as a direct readout of heme binding to the sensor, which would facilitate data collection using commonly available epifluorescence rather than more specialized fluorescence lifetime imaging microscopes, we implemented a strategy to correct for heme-independent environmental effects on our donor--acceptor fluorophores. For example, previous studies have shown that EYFP fluorescence is sensitive to chloride ions ([@r28]), the cytosolic concentration of which may be unknown in different biological contexts. To achieve this, we used CSY as a normalization control for any heme-independent environmental effects on the fluorophores. We evaluated the robustness of this approach by determining the efficiency of energy transfer for CH~49~Y (*E*~DA~^CH49Y^) and CSY (*E*~DA~^CSY^) in the absence and presence of 120 mM potassium chloride ([Fig. S7 *A* and *B*](#sfig07){ref-type="fig"}). Our data showed that this normalization approach effectively corrected for chloride-induced effects such that over a broad range of heme concentrations, *E*~DA~^CH49Y^/*E*~DA~^CSY^ at 0 and 120 mM KCl are indistinguishable ([Fig. S7*C*](#sfig07){ref-type="fig"}). We used our in vitro data for *E*~DA~^CH49Y^ and *E*~DA~^CSY^ ([Fig. 2*D*](#fig02){ref-type="fig"}) to establish a calibration curve defining the relationship between normalized efficiency of CH~49~Y energy transfer (*E*~DA~^CH49Y^/*E*~DA~^CSY^) and heme concentration ([Fig. 2*E*](#fig02){ref-type="fig"} and [*Materials and Methods*](#s7){ref-type="sec"}).

![Referencing *E*~DA~ data for the CH~49~Y sensor to the CSY control corrects for potentially confounding effects of environmental interfering substances (such as chloride ions) on the spectral characteristics of the fluorescent proteins making up the sensor. Chloride alters the absorption spectrum (*A*), and the fluorescence spectrum and inherent FRET exhibited by the *apo*-CH~49~Y heme sensor (*B*). (*C*) The ratio of *E*~DA~(CH~49~Y) to *E*~DA~(CSY) eliminates the effects of chloride on the spectral properties of the heme sensor and facilitates accurate chloride-independent quantitation of heme over a broad concentration range.](pnas.1615195114sfig07){#sfig07}

Measuring Labile Cytosolic Heme in Live *P. falciparum* Parasites. {#s4}
------------------------------------------------------------------

We focused next on using our heme sensor to quantify cytosolic labile heme concentrations in *P. falciparum* using fluorescence microscopy imaging. First, we sought to establish that *E*~DA~ determined using fluorimetry and fluorescence imaging correlated well with each other, as this would facilitate external calibration curves ([Fig. 2*E*](#fig02){ref-type="fig"}) to be used for determining intracellular heme concentrations. To test this, we encapsulated solutions of purified sensor and control proteins into giant multilamellar vesicles (GMVs) and measured *E*~DA~ by fluorescence microscopy. In parallel, we determined *E*~DA~ for the same solutions using fluorimetry. Although GMVs emitted fluorescence consistent with the loaded proteins, only those containing CH~49~Y or CSY exhibited significant *E*~DA~ ([Fig. 3*A*](#fig03){ref-type="fig"}). These data showed that the mean apparent *E*~DA~ values determined by imaging and fluorimetry agreed closely ([Fig. 3*B*](#fig03){ref-type="fig"}). Furthermore, by encapsulating the *apo*-sensor minilibrary having a range of different *E*~DA~ values ([Fig. 2 *A*--*C*](#fig02){ref-type="fig"}), we determined that fluorescence imaging microscopy and fluorimetry yield highly correlated outcomes ([Fig. 3*C*](#fig03){ref-type="fig"}). Altogether, these data validated that *E*~DA~ determined by microscopy can be accurately translated into heme concentrations based on fluorimetrically determined calibration data.

![Encapsulation of sensor protein library into giant multilamellar vesicles (GMVs) to establish correlation between donor--acceptor energy transfer determined by fluorimetry versus microscopy. (*A*) Representative images of CH~49~Y, CSY, ECFP, EYFP, and ECFP+EYFP encapsulated in GMVs illustrate relative brightness in each fluorescence channel. (*B*) Distributions of *E*~DA~ for GMVs containing *apo*-CH~49~Y (blue solid line) and CSY (red dashed line). (*C*) *E*~DA~ for the sensor library described in [Fig. 2*A*](#fig02){ref-type="fig"} determined by microscopy are plotted against those determined by fluorimetry. Error bars represent 95% CIs.](pnas.1615195114fig03){#fig03}

Next, we created clonal parasite lines on an NF54^attB^ ([@r29]) background separately expressing the CH~49~Y sensor and CSY control. We also created several spectral control cell lines expressing ECFP, EYFP, and both ECFP and EYFP as individual proteins for calibrating *E*~DA~ calculations. All lines homogenously expressed the respective proteins within the parasite's cytosol as determined by epifluorescence microscopy ([Fig. 4*A*](#fig04){ref-type="fig"}) and flow cytometry ([Fig. S8](#sfig08){ref-type="fig"}). We also confirmed by Western blot that both CH~49~Y and CSY were expressed as full-length proteins, thus eliminating proteolysis or premature translational termination as potential confounding factors in our subsequent data analyses ([Fig. 4*B*](#fig04){ref-type="fig"}).

![Using genetically encoded heme sensor to measure cytosolic labile heme concentrations in *P. falciparum*. (*A*) Representative images of CH~49~Y, CSY, ECFP, EYFP, and ECFP+EYFP in trophozoite-stage *P. falciparum* parasites. (*B*) Anti-GFP Western blot of lysates obtained from trophozoite-stage parasites expressing CH~49~Y, CSY, and YFP. (*C*) Representative *E*~DA~ distributions for *P. falciparum* trophozoites expressing CH~49~Y (solid line) and CSY (dashed line). Using the calibration curve in [Fig. 2*E*](#fig02){ref-type="fig"} yields an average cytosolic labile heme concentration of 1.6 µM (95% CI: 1.56--1.61 µM) across 15 independent experiments. (*D*) Quantitation of cytosolic labile heme over the *P. falciparum* IDC. Representative images of Giemsa-stained parasites to confirm the parasite stage being analyzed are shown for each time point. Measurements of CH~49~Y and CSY lines were made in triplicate, resulting in nine ratio calculations as described in [*Materials and Methods*](#s7){ref-type="sec"}. Error bars represent 95% CIs.](pnas.1615195114fig04){#fig04}

![Analysis of CH~49~Y sensor and CSY control expression in trophozoite-stage *P. falciparum* by flow cytometry. The transgenic parasite pools (blue line) showed positive fluorescence over background (black) in the Pacific Blue (CFP only), AmCyan (CFP and FRET), and FITC (YFP) channels. Clonal parasites used in subsequent experiments (red) exhibited homogenous expression of the respective fluorophores.](pnas.1615195114sfig08){#sfig08}

During initial studies, we observed that normalized *E*~DA~^CH49Y^ for normally developing late-stage parasites \[0.69; 95% confidence interval (CI): 0.65--0.72\] was significantly lower than in heme-free GMVs (0.93; 95% CI: 0.91--0.95) ([Fig. 3*B*](#fig03){ref-type="fig"}). As expected, parasites expressing ECFP and EYFP as individual proteins exhibited a mean *E*~DA~ close to zero (95% CI: −0.013 to 0.0022). As both CH~49~Y and CSY are expressed as full-length proteins ([Fig. 4*B*](#fig04){ref-type="fig"}), degradation that preferentially reduces energy transfer for CH~49~Y relative to that of CSY would not account for this observation. Based on our calibration data ([Figs. 2*E*](#fig02){ref-type="fig"} and [3*C*](#fig03){ref-type="fig"}) and 15 independent experiments, we observed an average normalized *E*~DA~^CH49Y^ = 0.71 (95% CI: 0.710--0.716) in late-stage parasites, consistent with a 1.6 µM cytosolic labile heme pool (95% CI: 1.56--1.61 µM).

We then sought to understand the dynamics of this labile heme pool over the course of the 48-h *P. falciparum* intraerythrocytic developmental cycle (IDC). As previously discussed, hemoglobin degradation is a potential source of a labile cytosolic heme in the parasite ([@r13], [@r30]). As the quantity of hemoglobin degraded significantly increases during progression through the IDC, we wanted to determine whether labile cytosolic heme levels would similarly rise or whether these would be maintained at relatively constant levels throughout. Using highly synchronous parasite cultures, we monitored normalized *E*~DA~^CH49Y^ in ring-stage \[4 h postinvasion (hpi)\], trophozoite-stage (16 and 28 hpi), and schizont-stage (38 hpi) parasites. Intriguingly, the metabolic changes associated with progression through the IDC appear to have minimal effects on the labile cytosolic heme pool ([Fig. 4*D*](#fig04){ref-type="fig"}). This suggests that, despite increased hemoglobin degradation in the DV of trophozoite and schizont-stage parasites, labile heme levels in the cytosol are maintained within narrow limits during parasite development.

Quantitative Analysis of Perturbed Heme Homeostasis by Heme-Interacting Antimalarials. {#s5}
--------------------------------------------------------------------------------------

We next used our heme sensor to gain direct insight into a proposed mechanism of antimalarial drug action. Heme-interacting antimalarial drugs, such as chloroquine, comprise one of the most successful classes, yet fundamental aspects of their mechanism of action remain unknown. Indeed, a more detailed understanding of these mechanisms could potentially be exploited for developing the next generation of antimalarial drugs that are not immediately compromised due to cross-resistance ([@r31]). Heme-binding antimalarial drugs have been proposed to interfere with detoxification of hemoglobin-derived heme by inhibiting its crystallization into hemozoin, thereby increasing labile heme concentrations to toxic levels ([@r11]). However, the effects of inhibiting hemozoin formation in the DV on heme levels in other parasite compartments have been a challenging question to directly and quantitatively address. Therefore, we sought to use our sensor to specifically quantify changes in the concentration of cytosolic labile heme upon parasite exposure to chloroquine.

We first established that parasites expressing CH~49~Y and CSY did not show altered sensitivity to chloroquine by determining IC~50~ values. We determined that both lines had similar chloroquine IC~50~ values of 10.3--11.3 and 11.4--12.1 nM (95% CIs), respectively, which were comparable to that of the parental NF54^attB^ line (8.2--9.7 nM) ([Fig. 5*A*](#fig05){ref-type="fig"}). These data suggest that CH~49~Y does not directly interfere with chloroquine action by sequestering heme to prevent potential toxic effects associated with chloroquine-induced increases in labile heme levels. We then exposed highly synchronous ring-stage parasites expressing either CH~49~Y or CSY to various chloroquine concentrations, and determined cytosolic labile heme concentrations. In four independent experiments, we detected a significant increase in labile heme concentration with 60 nM chloroquine treatment compared with the untreated control (average ∆\[heme\] = +0.86 µM; *P* = 0.002) ([Fig. 5 *B* and *C*](#fig05){ref-type="fig"}). Because chloroquine binds heme, it is possible that it competes with our sensor and potentially interferes with accurate measurement of labile heme levels. We evaluated this in vitro by precomplexing 0.5 µM CH~49~Y and 0.5 µM CSY in parallel with 5 µM heme, titrating chloroquine levels and monitoring apparent changes in measured heme concentrations using normalized *E*~DA~ calculations as earlier described ([Fig. S9](#sfig09){ref-type="fig"}). These data show that increasing chloroquine concentrations reduces apparent labile heme levels. However, at stoichiometric or higher chloroquine:heme ratios, apparent labile heme levels detected plateaus at ∼50--60% of actual levels even at a 10-fold excess of chloroquine over heme concentrations. This suggests that chloroquine can lead to an underestimation of labile heme levels by up to ∼2.5-fold. Chloroquine, although applied at 60 nM in the media, accumulates over 1,000-fold in the parasite's DV to reach micromolar levels ([@r32]). However, the extent with which it "leaks" into the parasite's cytosol in our experiments cannot be easily determined. Nevertheless, using our in vitro data, we can place lower (∼2.8 µM) and upper (∼7 µM) bounds on labile cytosolic heme levels, assuming, respectively, that no chloroquine or a ≥1:1 ratio of chloroquine:heme is present in the cytosolic compartment.

![Quantifying the impact of chloroquine on cytosolic labile heme pool in *P. falciparum*. (*A*) Growth inhibition data comparing the sensitivity of parasites expressing CH~49~Y (blue) and CSY (red) to chloroquine. (*B*) Fold change in labile heme concentration at various chloroquine concentrations after 24-h exposures. Data are representative of three independent experiments. Error bars show 95% CI. (*C*) Cytosolic labile heme concentrations in parasites that were untreated or exposed to chloroquine (60 nM) or pyrimethamine (125 and 500 nM) for 32 h. Data are representative of three independent experiments. Error bars represent 95% CIs derived from bootstrapping calculations ([*Materials and Methods*](#s7){ref-type="sec"}).](pnas.1615195114fig05){#fig05}

![Analysis of the impact of chloroquine on the detection of heme by the CH~49~Y sensor. CH~49~Y (0.5 µM) and CSY were preequilibrated in parallel with heme (5 µM) and chloroquine levels titrated (0--50 µM) while determining apparent decreases in heme concentration using normalized *E*~DA~ measurements. Chloroquine gradually reduces the level of detectable heme, until a plateau is reached at ∼1:1 chloroquine:heme stoichiometry. Addition of chloroquine to 10-fold excess over heme does not further reduce the detectable level of heme beyond 50--60% of the actual concentration.](pnas.1615195114sfig09){#sfig09}

As a negative control, we treated highly synchronous ring-stage parasites with the antifolate pyrimethamine, which exerts its antimalarial activity by inhibiting DNA synthesis rather than interfering with heme metabolism. No increase in labile heme concentration was detected between the treated and untreated parasites ([Fig. 5*C*](#fig05){ref-type="fig"}), consistent with pyrimethamine's mode of action. Altogether, these data demonstrate that a model heme-interacting antimalarial compound specifically induces a significant increase in cytosolic labile heme that can be quantified using our heme sensor. These data also add biological insight by demonstrating that the increase in cytosolic labile heme is unlikely to be a generalized cytotoxic response, but rather one that is directly and specifically linked to chloroquine-mediated dysregulation of parasite heme homeostasis.

Discussion {#s6}
==========

Here, we report the development and application of a heme biosensor to measure cytosolic labile heme levels in live, blood-stage *P. falciparum* malarial parasites. Our approach is distinct from some previous strategies used to measure intracellular labile heme in providing the important advantages of obtaining quantitative information from intact cells. Several previous methods have relied on measuring the heme-dependent enzymatic activities of [l]{.smallcaps}-tryptophan-2,3-dioxygenase and ALAS ([@r33], [@r34]) natively present in select cell types or recombinantly expressed horseradish peroxidase (HRP) ([@r35]). Fractionation methods have also been reported ([@r16], [@r36]). These methods require cell lysis, which makes it difficult to confidently infer the subcellular localization of labile heme. Genetically encoded heme sensors, such as the one we have developed and two recently reported while this study was in progress ([@r37], [@r38]), can facilitate imaging and quantification of heme in different subcellular compartments in intact cells. Therefore, these tools should broadly enable determination of both the distribution and labile heme levels at subcellular and single-cell resolution.

Using our sensor, we show that *P. falciparum* maintains an ∼1.6 µM labile cytosolic heme pool throughout its development in RBCs. It is useful to place this finding in context of previous data on labile heme levels in other organisms and cell types. Several recent reports have used genetically encoded FRET ([@r37]), ratiometric fluorescence ([@r38]), and hemoprotein peroxidase sensors ([@r39], [@r40]) to measure labile heme in *Saccharomyces cerevisiae* and various mammalian cells. These data show that mean resting labile heme levels ranged from 20 to 40 nM in *S. cerevisiae* ([@r38]) and a subset of mammalian cell lines ([@r37]) to 433 \[95% CI: 186--683 nM ([@r40])\] in HEK293 kidney fibroblast cells and 614 nM \[95% CI: 183--1,042 nM ([@r39])\] in IMR90 lung fibroblast cells. When the medium was supplemented with heme, IMR90 cells accumulated labile heme to a maximum of ∼2 µM, suggestive of a threshold regulatory response ([@r39]). These data indicate that labile heme levels vary across cell types/organisms, and reach up to 2 µM. Our measurements in *P. falciparum* extend our understanding of labile heme levels by examining a pathogen with an unusual biology that establishes large heme fluxes through a specialized DV. Between 30 and 70% of the RBC hemoglobin is proteolytically degraded ([@r9], [@r10]) to release heme (∼15 mM), which is mostly crystallized to hemozoin. However, our data show that labile cytosolic heme levels---albeit somewhat higher---are reasonably comparable with those reported for HEK293 and IMR90 cells, which likely do not experience similarly large heme fluxes as *P. falciparum*. Altogether, these data reinforce the high efficiency with which hemoglobin-derived heme is confined to the DV, such that labile cytosolic levels remain relatively low and tightly regulated.

The source of heme used by the parasite to maintain this cytosolic pool is unknown, but scavenging from the DV where hemoglobin degradation is occurring, de novo biosynthesis, and uptake from extracellular sources are formal possibilities. Previous qualitative evidence suggests that blood-stage parasites synthesize heme de novo ([@r13], [@r14]), but the extent to which this contributes to the heme pool we measure is unknown. Moreover, recent studies have shown that the parasite's biosynthetic pathway is dispensable during blood-stage development ([@r13], [@r30]), suggesting that biosynthesis may not be a critical source of heme for the parasite during this stage. Developing parasites are also known to become increasingly permeable to extracellular low--molecular-weight solutes via the new permeability pathway ([@r41]), so labile heme could potentially be acquired via this route. However, the largest obvious flux of heme in blood-stage parasites is through hemoglobin degradation in the DV. Therefore, this seems to be a reasonable candidate source of heme for the parasite. Additional studies will be needed to definitively and quantitatively address this possibility.

Although the exact source and physiologic role(s) of this labile cytosolic heme pool remain to be defined, our data show that the heme-binding antimalarial drug chloroquine dysregulates this pool. Although chloroquine accumulates to high levels within the DV to interfere with heme crystallization ([@r11]), our data quantify the in situ increase in cytosolic heme levels that potentially arises due to heme escaping the DV as qualitatively described previously ([@r16]). It is important to emphasize that our sensor likely responds only to the soluble fraction of released heme, and not the fraction that becomes associated with the parasite membrane ([@r42]). Thus, our measurements do not reflect the total heme flux induced by chloroquine treatment. This distinction is important, as these two heme pools can potentially induce different outcomes. Membrane-associated heme will likely contribute to cell membrane damage, whereas increased soluble heme could induce cytosolic oxidative stress and/or directly interfere with critical protein function(s) ([@r43]). In this model, both heme pools can contribute to cytotoxicity. Alternatively, moderate increases in cytosolic heme may be tolerated without significantly increased toxicity, and increases in soluble heme levels may be directly sensed by the parasite to initiate critical heme-dependent changes in transcription ([@r1], [@r44], [@r45]), translation, and/or proteasome-mediated protein turnover ([@r46], [@r47]), as in other organisms. These may serve to coordinate changes in DV metabolism with nuclear and cytosolic events that either counteract or exacerbate any adverse effects induced by increased efflux of heme from the DV into the cytoplasm. The responses to increased heme flux induced by antimalarial compounds likely overlap with the mechanisms for maintaining heme homeostasis. Guided by this quantitative understanding of labile heme levels in *P. falciparum*, elucidating these mechanisms can stimulate development of therapeutic strategies that recapitulate important aspects of chloroquine's antimalarial mode(s) of action, while circumventing resistance mechanisms that now limit its effectiveness. Compounds that induce dysregulation of parasite labile heme pools and/or key heme-regulated processes may be especially promising leads given the extraordinary success of the 4-aminoquinoline antimalarial drug class.

Overall, we have used a genetically encoded heme sensor to examine a long-standing gap in our knowledge of labile heme pools in human malaria parasites. The improved ability to quantify heme in live parasites at subcellular resolution will be useful for gaining insight into how natural perturbations in or deliberate manipulation of labile heme levels contribute, respectively, to heme-dependent signaling and devising antimalarial therapeutic strategies.

Materials and Methods {#s7}
=====================

Molecular Cloning. {#s8}
------------------

A fragment of the *P. falciparum* HRP2 gene (109--916 bp) lacking the N-terminal signal peptide was amplified by PCR from plasmid MRA-67 (ATCC/MR4) and cloned into pET28b (Novagen) vectors containing ECFP and EYFP using standard restriction and ligation techniques. To generate sensors based on truncated *Pf*HRP2, a forward oligonucleotide primer was designed to anneal to a repeated *Pf*HRP2 sequence motif identified using MEME ([@r48]) and was used with a fixed reverse primer to PCR amplify fragments of varying sizes using the *Pf*HRP2 gene as a template. These were separated by agarose gel electrophoresis, and then cloned into ECFP and EYFP-containing vectors as above. Fragments mapped to full-length *Pf*HRP2, except for some minor in-frame insertion/deletion mutations in the histidine-rich repeats. For CH~18~Y, the oligonucleotide encoding the heme-binding motif (HHAHHAADA)~2~ was generated in a Klenow reaction and cloned as above. For expression in *P. falciparum*, coding sequences from pET28b-based vectors were PCR amplified and cloned using the Gibson Assembly Master Mix (New England Biolabs) to replace the ENR-GFP fusion protein in plasmid MRA-846 (ATCC/MR4).

Protein Expression and Purification. {#s9}
------------------------------------

Plasmids encoding sensor and control proteins were transformed into *Escherichia coli* strain BL21(DE3). Cultures were grown overnight at 37 °C in ZYM-505 media ([@r49]) supplemented with kanamycin. Saturated cultures were diluted 1:200 in kanamycin-containing ZYM-505 media and grown at 37 °C until OD~600~ = 0.6--0.8. Protein expression was induced by adding 0.1 mM isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside for 24 h at room temperature. Cells were harvested by centrifugation, and pellets were frozen and stored at −80 °C. For protein purification, cell pellets were thawed at room temperature and lysed with B-PER II bacterial protein extraction reagent (Thermo Scientific) supplemented with lysozyme, Benzonase (Novagen), and protease inhibitor mixture (Sigma-Aldrich). Lysates were clarified by centrifugation and applied to purification beads that had been previously washed with Equilibration/Wash Buffer \[50 mM Tris⋅HCl, pH 8.0, 200 mM NaCl, 5% (vol/vol) glycerol\]. Hexahistidine-tagged protein constructs were bound to HisPur Cobalt Resin (Thermo Scientific), whereas Strep-Tactin Superflow Plus (Qiagen) was used to bind Strep-tagged proteins. In both cases, lysates were incubated with purification beads for 1 h at 4 °C with gentle agitation. Purification beads were then washed extensively with ice-cold Equilibration/Wash Buffer, before loading on to a gravity-flow column. Hexahistidine-tagged proteins were eluted from the column with Elution Buffer H (50 mM Tris⋅HCl, pH 8.0, 200 mM NaCl, 500 mM imidazole, 5% glycerol). Strep-tagged proteins were eluted from the column with Elution Buffer S (50 mM Tris⋅HCl, pH 8.0, 200 mM NaCl, 2.5 mM desthiobiotin, 5% glycerol). Fractions were spectroscopically monitored using a NanoDrop spectrophotometer (Thermo Scientific), and those containing ECFP and/or EYFP were pooled and concentrated using Amicon Ultra-15 centrifugal filters (Thermo Scientific). Concentrated protein solutions were then dialyzed against 2× PBS, pH 7.4. Glycerol was then added to 50% and protein solutions were stored at −20 °C.

Absorbance Titrations. {#s10}
----------------------

Titrations to measure heme-binding affinity and stoichiometry were performed as previously described ([@r19], [@r23]). Stock solutions of recombinant protein were prepared in 100 mM Hepes-KOH, pH 7.0. Stock solutions of 1 mM hemin (Sigma-Aldrich) were prepared in DMSO. All concentrations were verified spectrophotometrically. Heme-binding titrations were performed in 3-mL-capacity quartz cuvettes at 37 °C with stirring using a Cary 100 Bio Spectrophotometer (Varian). Heme titrations were performed with 2 mL of 0.5 µM protein solution, using 2 mL of Hepes-KOH as a reference. For each concentration, heme was added to both the sample and reference cells and stirred for 5 min before difference spectra were measured. Heme binding was quantified based on a differential absorption peak at 416 nm. The ∆*A*~416nm~ versus heme concentration data were plotted and analyzed using Prism (GraphPad Software).

Fluorescence Titrations and Energy Transfer Efficiency Calculations. {#s11}
--------------------------------------------------------------------

Hemin stock solution was serially diluted in Hepes-KOH in a 96-well plate. Protein stock solution was added to 0.5 µM final concentration using a multichannel pipetter, and the plate was incubated at 37 °C for 5 min. Fluorescence spectra were measured using a Fluoromax-3 fluorimeter (Horiba Jobin Yvon). ECFP was excited at 420 nm, with emission scanning from 440 to 600 nm. EYFP was excited at 500 nm, with emission scanning from 505 to 600 nm. Energy transfer efficiencies were calculated using the ratio~A~ method as previously described ([@r6], [@r27]).

Fluorescence Lifetime Spectroscopy. {#s12}
-----------------------------------

The multiphoton FLIM microscope consisted of a Ti:sapphire laser (Tsunami HP; Spectra Physics), tunable between 780 and 880 nm ([Fig. S2](#sfig02){ref-type="fig"}). Power control was achieved using a half waveplate and Glan-Laser polarizer. The beam first struck a tilted glass coverslip beam splitter where part of the beam was focused onto a photodiode to create a reference pulse. The majority of the pulse intensity passed through the beam splitter to the rest of the microscope. The beam was subsequently reflected off a dichroic beam splitter (675DCSX; Chroma Technology) and two galvanometric scanning mirrors (6350; Cambridge Technology) before entering the scan lens, which produced a moving focal spot at the image plane of the microscope (Axiovert 100TV; Zeiss). The scanning mirrors were controlled using software written in-house, and the synchronization signals were created using an FPGA (Spartan XCS30; Xilinx).

The spot in the image plane was imaged onto the sample by the microscope objective (C-Apochromat, 40×, water immersion; 44-00-52; Zeiss), and the resulting fluorescence emission was captured by the objective, descanned by the scanning mirrors, and passed through the dichroic mirror and filter (ESP650; Chroma Technology), where it was focused onto a photomultiplier tube (R7400P; Hamamatsu). The signal from the photomultiplier and the signal from the reference photodiode were measured by a Time-Correlated Single Photon Counting Card (SPC-730; Becker and Hickl), and the resulting image was displayed using the Becker and Hickl software.

The instrument response was compensated for by measuring a sample (fluorescein in pH 9 DMSO solution, from R14782 reference sample kit; Life Technologies; known lifetime of 4.1 ns) and deconvolving the known decay curve from the measured curve to yield the instrument response. This instrument response was then deconvolved from every measured curve to yield a corrected decay curve. After this correction, the exponentially decaying section of the curve was taken from the data, and a "single exponential decay with unknown offset" function was fitted to the data to recover the fluorescence lifetime while compensating for the small background in the measurement. All calculations were performed using MATLAB 2011b (MathWorks).

Malaria Parasite Culture. {#s13}
-------------------------

Blood-stage malaria parasites were cultured at 2% hematocrit in 5% O~2~ and 5% CO~2~ in RPMI medium 1640 supplemented with 5 g/L AlbuMAX II (Life Technologies), 2 g/L NaHCO~3~, 25 mM Hepes-KOH, pH 7.4, 1 mM hypoxanthine, and 50 mg/L gentamicin. Strains were synchronized using a solution of 0.3 M alanine supplemented with 25 mM Hepes-KOH, pH 7.4. Parasite transfections were performed by preloading RBCs with plasmid DNA by electroporation. All expression constructs were integrated at the *cg6* locus in NF54^attB^ parasites ([@r29]) by cotransfecting with the pINT plasmid (MRA-847) ([@r50]). For each transfection, 100 µL of washed RBCs was mixed with 25--50 µg of plasmid DNA and then electroporated with 8 × 1-ms square pulses at 365 V. Late-stage parasites were then split to 0.1% parasitemia using one-half of the loaded RBCs. After 48 h, transfected cultures were split 1:2 using the remainder of the loaded RBCs. After another 48 h, cultures were split again, and drug selection was initiated. Drug-resistant parasites were then cloned via limiting dilution, and clones were screened for expression of ECFP and/or EYFP using flow cytometry.

Preparation of GMVs. {#s14}
--------------------

Stock solutions of 1,2-dioleoyl-*sn*-glycero-3-phospho-(1′-rac-glycerol) (DOPG) and 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) (Avanti Polar Lipids) in chloroform were mixed in a 1:1 ratio, and 1 µmol of total lipid was added to a glass scintillation vial. Lipid films were deposited by overnight evaporation of the chloroform at room temperature. Lipid films were then hydrated by incubating scintillation vials in a humidified 70 °C oven for 6 h. Vesicles were prepared by gently adding protein solutions (0.5 µM protein in 100 mM Hepes-KOH, pH 7, plus 50 mM sucrose) and incubating overnight at room temperature in the dark. After incubation, vesicles were washed extensively in Hepes-KOH plus 50 mM glucose and imaged.

In Situ Analysis of Donor--Acceptor Energy Transfer. {#s15}
----------------------------------------------------

Synchronized late-stage parasite cultures were washed and resuspended in Opti-Klear media (Marker Gene Technologies) at 0.05% hematocrit for imaging. Culture suspensions were added to glass-bottom 24-well plates (In Vitro Scientific) pretreated with 0.1% polyethyleneimine. Cultures were imaged using a Nikon Ti microscope using the following filter sets: ECFP \[436 nm/20 nm excitation (EX), 455 nm long pass (LP), 480 nm/40 nm emission (EM)\], FRET (436 nm/20 nm EX, 455 nm LP, 535 nm/30 nm EM), and YFP (500 nm/20 nm EX, 515 nm LP, 535 nm/30 nm EM). Images were acquired using an Andor iXon+ 897 EMCCD camera and MetaMorph acquisition software (Molecular Devices). Images were processed using Biosensor Processing Software, version 2.1 ([@r51]). Briefly, images were shade-corrected using averaged reference images, and segmentation values were chosen for each channel by manual inspection to draw background masks, which were then grown using a 5-pixel radius. Background subtraction was performed according to software defaults. The FRET channel was corrected for bleedthrough from CFP and cross talk from YFP using correction factors of 0.4 and 0.1, respectively. Images were obtained by calculating the ratio between the corrected FRET channel image and the YFP image, and manually curated to identify individual cells. Average per-cell *E*~DA~ for CH~49~Y and CSY strains were calculated and tabulated using the FIJI distribution of ImageJ ([@r52]). A bootstrapping algorithm with 10,000 iterations was used to estimate the ratio of averages between CH~49~Y and CSY energy transfer distributions, correct for the offset measured between microscopy and fluorimetry data, and compute a 95% CI. The ratio of averages and the CI bounds were used to calculate heme concentrations according to the following empirically determined relationship between normalized *E*~DA~^CH49Y^ and heme ([Fig. 2 *D* and *E*](#fig02){ref-type="fig"}):$$\text{Normalized}\, E_{\text{DA}}^{\text{Sensor}} = \,\frac{E_{\text{DA},{\,\text{CH}}_{49}\text{Y}}}{E_{\text{DA},\,\text{CSY}}} = \,\frac{0.41e^{- 0.18{\lbrack\text{Heme}\rbrack}} - 0.027}{0.41 - 0.01\left\lbrack \text{Heme} \right\rbrack}.$$

Calculations were performed using MATLAB R2013a software (MathWorks).

Western Immunoblotting. {#s16}
-----------------------

Parasites were obtained by lysing 180 µL of infected RBCs with an ice-cold solution of 0.1% saponin (Fluka) in PBS and incubating on ice until solutions cleared. Parasite pellets were washed extensively with saponin--PBS solution to remove residual hemoglobin and then lysed with the addition of 200 µL of 1× SDS--urea sample buffer (40 mM Tris base, 80 mM Gly--Gly, 40 mM DTT, 1.6% SDS, and 6.4 M urea adjusted to pH 6.8 with HCl). Parasite lysates were diluted 1:10 before gel electrophoresis and transfer. Blots were probed with a mouse monoclonal anti-GFP (B-2) primary antibody (catalog no. SC-9996; Santa Cruz Biotechnology) diluted 1:2,000, and a goat anti-mouse secondary antibody conjugated to HRP (H+L) (catalog no. 71045; Novagen), and visualized using SuperSignal West Femto chemiluminescent substrate (Thermo Scientific).
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